Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Epoetin Alfa

Epoetin Alfa

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of Epoetin Alfa

29 trials tracked of Epoetin Alfa: 18 in phase 3 or 4 and 3 with published results. The most-cited published study has 207 citations.

29Trials tracked
18Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 5 Phase 3 13 Phase 2 9 Other / NA 2
  1. Phase 3 High-dose Erythropoietin for Asphyxia and Encephalopathy Completed · 207 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis Completed · 49 cited
  3. Phase 4 Impact of Erythropoietin on Hematological Adaptations and Physical Performance Completed · 6 cited
  4. Phase 4 Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed
  5. Phase 4 Nephropathy In Type 2 Diabetes and Cardio-renal Events Completed
  6. Phase 4 Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients Completed
Show 23 more trials
  1. Phase 4 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) Completed
  2. Phase 3 Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2) Completed
  3. Phase 3 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. Completed
  4. Phase 3 A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia Completed
  5. Phase 3 Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer Completed
  6. Phase 3 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis Completed
  7. Phase 3 PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients Completed
  8. Phase 3 A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia Completed
  9. Phase 3 A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia. Completed
  10. Phase 3 Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants Completed
  11. Phase 3 Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Completed
  12. Phase 3 Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes Completed
  13. Phase 2 Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) Completed
  14. Phase 2 Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS Completed
  15. Phase 2 Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA Completed
  16. Phase 2 A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities. Completed
  17. Phase 2 Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis Completed
  18. Phase 2 REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction Completed
  19. Phase 2 Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) Completed
  20. Phase 2 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed
  21. Phase 2 Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa Completed
  22. N/A Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma Completed
  23. N/A Effects of Exercise in Combination With Epoetin Alfa Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review examines early erythropoiesis-stimulating agents for preterm infants across multiple clinical outcomes and safety endpoints
Neurology Sys. Review
Systematic review examines early erythropoiesis-stimulating agents for preterm infants across multiple clinical outcomes and safety endpoints Early blood boosters may lower severe brain injury risk in premature babies
A systematic review of 37 trials involving 6,724 preterm or low-birthweight infants found that early erythropoiesis-stimulating agents likel…
A review of 37 studies suggests early blood boosters might lower severe brain injury and severe gut illness in premature infants without rai…
Cochrane May 22, 2026